[go: up one dir, main page]

NO20035438L - Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav - Google Patents

Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav

Info

Publication number
NO20035438L
NO20035438L NO20035438A NO20035438A NO20035438L NO 20035438 L NO20035438 L NO 20035438L NO 20035438 A NO20035438 A NO 20035438A NO 20035438 A NO20035438 A NO 20035438A NO 20035438 L NO20035438 L NO 20035438L
Authority
NO
Norway
Prior art keywords
norapomorphine
apomorphine
prodrugs
propyl
derivatives
Prior art date
Application number
NO20035438A
Other languages
English (en)
Other versions
NO20035438D0 (no
Inventor
Hakan Vilhelm Wikstrom
Thomas Ivo Franciscus Cremers
Durk Dijkstra
Original Assignee
Axon Biochemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Biochemicals Bv filed Critical Axon Biochemicals Bv
Publication of NO20035438D0 publication Critical patent/NO20035438D0/no
Publication of NO20035438L publication Critical patent/NO20035438L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20035438A 2001-06-08 2003-12-05 Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav NO20035438L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102036A SE0102036D0 (sv) 2001-06-08 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PCT/SE2002/001106 WO2002100377A1 (en) 2001-06-08 2002-06-07 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF

Publications (2)

Publication Number Publication Date
NO20035438D0 NO20035438D0 (no) 2003-12-05
NO20035438L true NO20035438L (no) 2004-02-05

Family

ID=20284413

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035438A NO20035438L (no) 2001-06-08 2003-12-05 Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav

Country Status (19)

Country Link
US (2) US20040220205A1 (no)
EP (1) EP1401398A1 (no)
JP (1) JP2005508865A (no)
KR (2) KR20090085162A (no)
CN (1) CN1286451C (no)
AU (1) AU2002309429B2 (no)
BR (1) BR0210261A (no)
CA (1) CA2449571A1 (no)
CZ (1) CZ20033332A3 (no)
EA (1) EA008409B1 (no)
HU (1) HUP0400200A3 (no)
IL (1) IL158898A0 (no)
MX (1) MXPA03011314A (no)
NO (1) NO20035438L (no)
NZ (1) NZ529623A (no)
PL (1) PL367883A1 (no)
SE (1) SE0102036D0 (no)
WO (1) WO2002100377A1 (no)
ZA (1) ZA200309048B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EP2296652B1 (en) * 2008-06-30 2017-11-08 Afgin Pharma, Llc Topical regional neuro-affective therapy
US20120196889A1 (en) 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
FI2442650T4 (fi) 2009-06-12 2025-08-06 Sunovion Pharmaceuticals Inc Kielen alle annettava apomorfiini
DK2651357T3 (da) 2010-12-16 2020-06-02 Sunovion Pharmaceuticals Inc Sublinguale film
KR101374500B1 (ko) * 2012-10-09 2014-03-13 울산대학교 산학협력단 Ｒ(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
RU2017123762A (ru) * 2014-12-23 2019-01-24 Нейродерм Лтд Кристаллические формы апоморфина и их применение
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
EP3265081A4 (en) 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
EP3285771B1 (en) 2015-04-21 2025-02-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
EP3355887A1 (en) 2015-09-28 2018-08-08 EVER Neuro Pharma GmbH Aqueous composition of apomorphine for subcutaneous administration
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
MX2020005366A (es) 2017-11-24 2020-08-13 H Lundbeck As Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
CN113727974B (zh) 2019-05-21 2025-01-07 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2023552699A (ja) 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP2025520542A (ja) 2022-06-15 2025-07-03 エバー ニューロ ファーマ ゲーエムベーハー アポモルヒネプロドラッグおよびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
US4120860A (en) * 1977-05-10 1978-10-17 Cooper Lab 3-Aryl-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5222236A (en) * 1988-04-29 1993-06-22 Overdrive Systems, Inc. Multiple integrated document assembly data processing system
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators

Also Published As

Publication number Publication date
CN1531420A (zh) 2004-09-22
EP1401398A1 (en) 2004-03-31
CZ20033332A3 (cs) 2004-12-15
ZA200309048B (en) 2004-11-22
HUP0400200A2 (hu) 2004-06-28
MXPA03011314A (es) 2004-12-06
JP2005508865A (ja) 2005-04-07
EA008409B1 (ru) 2007-04-27
WO2002100377A1 (en) 2002-12-19
NZ529623A (en) 2008-04-30
PL367883A1 (en) 2005-03-07
US20080145417A1 (en) 2008-06-19
CA2449571A1 (en) 2002-12-19
KR20040007644A (ko) 2004-01-24
HUP0400200A3 (en) 2008-03-28
NO20035438D0 (no) 2003-12-05
SE0102036D0 (sv) 2001-06-08
KR20090085162A (ko) 2009-08-06
CN1286451C (zh) 2006-11-29
EA200400007A1 (ru) 2004-04-29
IL158898A0 (en) 2004-05-12
AU2002309429B2 (en) 2007-08-09
BR0210261A (pt) 2004-07-20
US20040220205A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
NO20020976D0 (no) Retarderte, orale, farmasöytiske administreringsformer
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
IS6892A (is) Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn
NO20042155L (no) N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
NO20024176L (no) Farmasöytiske preparater inneholder derivater av 3-amino- azetidin, de nye derivater og deres fremstilling
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20014013D0 (no) 16-halogenepotilonderivater, fremgangsmater for fremstilling av dem og deres farmasoytiske anvendelse
NO20042993L (no) Formulering og doseringsform for kontrollert levering av terapeutiske midler
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
NO20021599D0 (no) Nye farmasöytiske sammensetninger av anti-tuberkulose legemidler og fremgangsmåte for deres fremstilling
NO20033384D0 (no) Farmasöytisk formulering
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20033785L (no) Farmasöytisk formulering
IS6508A (is) Lyfjasamsetningar af glycogen fosfórýlasa lötum
NO20035627D0 (no) Farmasöytisk formulering
DK1210119T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20040047L (no) Farmasoytisk formulering for intramuskulaer administrering av fulvestrant
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
NO20043576L (no) Pharmaceutical formulation comprising melatonin
EE200300548A (et) Uudsed 5-tio-ß-D-ksülopüranosiidi derivaadid, nende valmistamise meetod, neid sisaldavad farmatseutilised kompositsioonid ja nende terapeutiline kasutamine
NO331169B1 (no) Krystallinsk form av et fenyletanolamin, fremstilling derav og farmasoytisk preparat og legemiddel omfattende den samme
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application